British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.
British Columbia's Biosimilars Initiative successfully saved about $732 million over 5 years by switching over 40,000 patients from reference biologics to biosimilars, while maintaining equivalent health outcomes and reinvesting the savings into the province's public payer program (BC PharmaCare) to enhance drug coverage and health care services.1
The province published its 5-year results in a report on the program’s impact on patients and BC PharmaCare spending. The program began in 2019 and British Columbia was the first Canadian jurisdiction to adopt a biosimilar switching policy.2 Since, 10 other jurisdictions (Alberta, New Brunswick, Northwest Territories, Nova Scotia, Newfoundland and Labrador, Quebec, Saskatchewan, Newfoundland, Yukon, and Ontario) have adopted their own policies.3
Biologics sales in Canada have grown steadily over time, representing over one-third of total pharmaceutical sales in 2020. Adalimumab is one of the top expenditures for BC PharmaCare, costing $97.66 million between 2020 and 2021 and is expected to grow annually by 14.2%.
“We are focused on reducing pharmaceutical costs to ensure people in [British Columbia] have a sustainable health-care system now and in the future, and our biosimilar initiative continues to do just that,” said Adrian Dix, Minister of Health for the province, in a statement.4 “Since our province led the country with the use of biosimilars in 2019, thousands of people have switched to a biosimilar, saving money and allowing us to expand our BC PharmaCare program and coverage further.”
Key features of British Columbia's standardized framework for biosimilar switching include:
This framework ensures patients and providers have time to manage the transition, discuss concerns, and receive accurate information to minimize negative expectations and promote positive treatment experiences. It also includes administrative support for the transition process and options for exceptional coverage if needed.
The adoption of biosimilars among BC PharmaCare patients was substantial, ranging from 91% to 95% for various biologics, 24 months following the transition period. The authors noted a low rate of patient switching back to reference biologics was particularly noteworthy. For instance, only 1% of infliximab users reverted to the reference biologic, with similarly low rates observed for rituximab and adalimumab biosimilars. The author said that the findings suggested a high level of acceptance and continued utilization of biosimilars within the BC PharmaCare patient population.
Biosimilars for adalimumab, enoxaparin, and rituximab—which were added to the program during the second or third phase—experienced more rapid uptake compared with the earlier phases. This accelerated adoption is likely indicative of increased familiarity and confidence among both patients and prescribers in the biosimilar policy. Although most biosimilars achieved a switch rate of over 95% after the transition period, rapid-acting insulins (insulin aspart and insulin lispro) did not reach this level. This was attributed to the fact that Health Canada has not yet approved rapid-acting biosimilar insulins for use in all brands of insulin pumps. Consequently, the Ministry of Health extended coverage for the reference rapid-acting insulin for patients who use specific insulin pumps.
The majority of reinvestments from savings generated by biosimilar adoption was directed toward enhancing the BC PharmaCare program through improvements in consultation with clinicians, patients, and caregivers. The potential upcoming drug listings that may be facilitated by biosimilar savings include:
References
1. British Columbia government. B.C.’s biosimilars initiative: a report on patient and financial impact. British Columbia government. June 14, 2024. Accessed June 17, 2024. http://news.gov.bc.ca/files/BCBiosimilarsInitiativeAReportonPatientandFinancialImpact_June%202024.pdf
2. Davio K. British Columbia becomes the first Canadian province to mandate a switch to biosimilars. The Center for Biosimilars®. May 28, 2019. Accessed June 17, 2024. https://www.centerforbiosimilars.com/view/british-columbia-becomes-the-first-canadian-province-to-mandate-a-switch-to-biosimilars
3. Jeremias S. Prince Edward Island announced new biosimilar switching policy. The Center for Biosimilars. October 14, 2023. Accessed. June 17, 2024. https://www.centerforbiosimilars.com/view/prince-edward-island-announces-new-biosimilar-switching-policy
4. B.C.’s biosimilar initiative saves money, reinvests to expand drug coverage. News release. British Columbia government. June 14, 2024. Accessed June 17, 2024. https://news.gov.bc.ca/releases/2024HLTH0081-000927
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Gastroenterology Roundup: November 2024
November 30th 2024In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms grew; Celltrion expanded its portfolio; and Global Biosimilars Week focused on improving affordability and equity.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.